Results of the RESILIENT study were recently presented at the British Society of Interventional Radiology (BSIR) meeting and showed that primary stenting with the LifeStent (Bard) was superior to a PTA-alone strategy in claudicants with SFA/proximal popliteal lesions ≤150mm, at two years.
Two-hundred and six patients (claudicants) were enrolled at 24 sites and primary patency was achieved in 80% of patients in the stent group vs. 38% in the PTA group, and freedom from target lesion revascularisation (TLR) was 87% in the stent group vs. 46% in the PTA group.
Most read
Features
Profiles
